US Pharma MarketingTango plans Phase 3 pancreatic cancer study after combo success
Tango Therapeutics reports 92% ORR from vopimetostat plus daraxonrasib combo in pancreatic cancer, plans Phase 3 study later this year. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Will 2026 be remembered as the year when pancreatic cancer finally became treatable?
Following Revolution Medicines’ smashing success at the annual American Society of Clinical Oncology meeting last week, the company’s lead drug daraxonrasib is ...
Source: Endpoints News